Class-specific relative genetic contribution for key antiretroviral drugs

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3074-3079

  Siccardi, Marco ^a   Olagunju, Adeniyi ^a,b   Simiele, Marco ^c   D'Avolio, Antonio ^c   Calcagno, Andrea ^c   Di Perri, Giovanni ^c   Bonora, Stefano ^c   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC PARAMETERS; RELATIVE GENETIC CONTRIBUTION; AGED; CHEMISTRY; MIDDLE AGED; PHARMACOGENETICS; PLASMA; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PLASMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84949034609     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv207     Document Type: Article

References (44)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services, 2010; 1-166.
2. Gonzalez de Requena D, Bonora S, Vigano O et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother 2011; 66: 192-200.
3. Rosario MC, Poland B, Sullivan J et al. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 2006; 42: 183-91.
4. McFadyen L, Jacqmin P, Wade JR et al. Maraviroc (MVC) exposure - efficacy relationship in treatment-experienced HIV-1-infected patients. In: AIDS Conference/EACS, Madrid, Spain, 2007. Poster P4.1/06.
5. la Porte C. Inhibitory quotient in HIV pharmacology. Curr Opin HIV AIDS 2008; 3: 283-7.
6. Hartkoorn RC, Kwan WS, Shallcross V et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20: 112-20.
7. Minuesa G, Huber-Ruano I, Pastor-Anglada M et al. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther 2011; 132: 268-79.
8. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-63.
9. Child M, Agarwala S, Boffito M et al. Effect of food on the pharmacokinetics of atazanavir when administered with food in healthy subjects. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 2007. Abstract 25.
10. Giguere P, Burry J, Beique L et al. The effect of food on the pharmacokinetics of atazanavir/ritonavir 300/100mg daily in HIV-infected patients. In: Abstracts of the Eleventh International Workshop on Clinical Pharmacology of HIV Therapy Sorrento, Italy, 2010. Abstract 30.
11. Kakuda TN, Van De Casteele T, Petrovic R et al. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther 2014; 19: 597-606.
12. Crauwels HM, van Heeswijk RP, Buelens A et al. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol 2013; 53: 834-40.
13. Moss DM, Siccardi M, Back DJ et al. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother 2013; 68: 1627-34.
14. Moss DM, Siccardi M, Murphy M et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother 2012; 56: 3020-6.
15. Mahungu T, Smith C, Turner F et al. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 2009; 10: 310-7.
16. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
17. Saitoh A, Sarles E, Capparelli E et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-9.
18. Klein K, Lang T, Saussele Tet al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15: 861-73.
19. Siccardi M, D'Avolio A, Nozza S et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T > C polymorphism. Pharmacogenet Genomics 2010; 20: 759-65.
20. Siccardi M, D'Avolio A, Baietto L et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47: 1222-5.
21. Schipani A, Egan D, Dickinson L et al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther 2012; 17: 861-8.
22. Wyen C, Hendra H, SiccardiMet al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011; 66: 2092-8.
23. Schipani A, Wyen C, Mahungu T et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 2011; 66: 1332-9.
24. Liptrott NJ, Pushpakom S, Wyen C et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics 2012; 22: 10-9.
25. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-53.
26. Cortes CP, Siccardi M, Chaikan A et al. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit 2013; 35: 78-83.
27. Kohlrausch FB, de Cassia Estrela R, Barroso PF et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010; 69: 95-8.
28. Olagunju A, Schipani A, Siccardi M et al. CYP3A4*22 (c.522-191 C.T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenet Genomics 2014; 24: 459-63.
29. Lubomirov R, Arab-Alameddine M, Rotger M et al. Pharmacogeneticsbased population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenet Genomics 2013; 23: 9-18.
30. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-9.
31. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-88.
32. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003; 13: 581-4.
33. Micheli JE, Chinn LW, Shugarts SB et al. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics 2013; 23: 591-6.
34. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
35. D'Avolio A, Simiele M, Baietto L et al. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010; 32: 86-92.
36. D'Avolio A, Sciandra M, Siccardi M et al. A new assay based on solidphase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J Chromatogr Sci 2008; 46: 524-8.
37. Arab-Alameddine M, Di Iulio J, Buclin T et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85: 485-94.
38. Kwara A, Lartey M, Sagoe KWet al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23: 2101-6.
39. Van Gelder J, Deferme S, Annaert P et al. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 2000; 28: 1394-6.
40. van Gelder J, Deferme S, Naesens L et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30: 924-30.
41. Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol 2014; 5: 248.
42. Siccardi M, D'Avolio A, Rodriguez-Novoa S et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit 2012; 34: 232-5.
43. Hirano A, Ikemura K, Takahashi M et al. Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients. AIDS Res Hum Retroviruses 2012; 28: 776-9.
44. Wenning LA, Petry AS, Kost JT et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009; 85: 623-7.